EurekAlert!

Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells, Without Toxicity to Healthy Tissue, in Preclinical Research

PHILADELPHIA — Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and ...
EurekAlert!

CDH17 CARTs attack tumor but spare normal tissue (IMAGE)

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
GEN

CAR T Cells Target CDH17 Antigen, Suppress GI Tumor Cells, Overlook Healthy Cells

Chimeric antigen receptor (CAR) therapies have shown that they can take on blood cancers, that is, leukemias and lymphomas. Solid tumors are another matter. Indeed, solid tumors such as neuroendocrine ...
Business Wire

SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer

PRAGUE and LONDON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate ...
Morningstar

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in ...
Morningstar

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: ...